Last reviewed · How we verify

Fablyn — Competitive Intelligence Brief

Fablyn (LASOFOXIFENE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: lasofoxifene. Area: Bone.

marketed lasofoxifene Estrogen receptor Bone Small molecule Live · refreshed every 30 min

Target snapshot

Fablyn (LASOFOXIFENE) — Dr. Friedrich Eberth Arzneimittel GmbH.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Fablyn TARGET LASOFOXIFENE Dr. Friedrich Eberth Arzneimittel GmbH marketed lasofoxifene Estrogen receptor 2009-01-01
Orserdu ELACESTRANT Stemline Therap marketed Estrogen Receptor Antagonist [EPC] Estrogen receptor 2023-01-01
Nextstellis ESTETROL Mayne Pharma marketed Estrogen Estrogen receptor 2021-01-01
Cerianna FLUOROESTRADIOL F-18 GE HealthCare marketed Radioactive Diagnostic Agent [EPC] Estrogen receptor 2020-01-01
Duavee conjugated-estrogens-bazedoxifene Pfizer marketed Estrogen [EPC] estrogen receptors α and β 2013-01-01
Duavee BAZEDOXIFENE Wyeth Pharms Pfizer marketed Estrogen [EPC] estrogen receptors (ER) α and β 2013-01-01
Osphena OSPEMIFENE Duchesnay marketed Estrogen Agonist/Antagonist [EPC] Estrogen receptor beta 2013-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (lasofoxifene class)

  1. Dr. Friedrich Eberth Arzneimittel GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fablyn — Competitive Intelligence Brief. https://druglandscape.com/ci/lasofoxifene. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: